Who makes NP137 DL and RP2D?

NP137 DL and RP2D is developed by Centre Leon Berard.

What development phase is NP137 DL and RP2D in?

NP137 DL and RP2D is in Phase 1.

Last reviewed 2026-04-20 · How we verify

NP137 DL and RP2D

Centre Leon Berard · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	NP137 DL and RP2D
Sponsor	Centre Leon Berard
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NP137 DL and RP2D CI brief — competitive landscape report
NP137 DL and RP2D updates RSS · CI watch RSS
Centre Leon Berard portfolio CI